<DOC>
	<DOCNO>NCT00483756</DOCNO>
	<brief_summary>A new immunosuppressive drug , base inhibition important enzyme immune system call JAK3 , develop Pfizer prevent transplant rejection . In research study , JAK3 inhibitor cyclosporine give new kidney transplant patient 12 month . Patients assign one three treatment group receive kidney transplant . Two treatment group receive 2 different dose regimen JAK3 inhibitor take mouth . The third treatment group standard-of-care control arm . Patients continue take assign study medication 12 month well standard transplant medication prednisone .</brief_summary>
	<brief_title>Study JAK3 Inhibitor Prevention Acute Rejection Kidney Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Tofacitinib</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Recipient firsttime kidney transplant Between age 18 70 year , inclusive Recipient nonkidney transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Immunosuppression</keyword>
	<keyword>JAK3 inhibitor</keyword>
	<keyword>kidney transplantation .</keyword>
</DOC>